More on INCY
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $113.36 |
|
|||
| Open | $114.70 | ||||
| 52 Wk High | $118.49 | ||||
| 52 Wk Low | $55.00 | ||||
| Day High | $116.00 | ||||
| Day Low | $113.31 | ||||
| P/E | N/A | ||||
| EPS | $-0.56 | ||||
| Volume | 433,178 | ||||
- H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
- Star Therapeutics to present VGA039 trial data at ISTH 2026
- Star Therapeutics to Present Complete Data from Phase 1/2 Multidose Study of VGA039 in Von Willebrand Disease at ISTH 2026 Congress
- Incyte's ruxolitinib cream gets positive EU review for eczema
- Incyte Announces Positive CHMP Opinion for Opzelura® (ruxolitinib) Cream for the Treatment of Adults with Moderate Atopic Dermatitis
- Incyte (INCY) PT Raised to $113 at UBS
- H.C. Wainwright Reiterates Buy Rating on Incyte (INCY)
- Incyte (INCY) PT Raised to $105 at Truist Securities
- Incyte settles CMS lawsuit over Opzelura Medicaid rebate rules
- Form 8-K INCYTE CORP For: Jun 22
Entities mentioned with INCY
- FDA | View Related Stories »
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- PDUFA | View Related Stories »
- Show More...
